within Pharmacolibrary.Drugs.ATC.N;

model N06AF04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 1.2166666666666667e-06,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0023000000000000004,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06AF04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tranylcypromine is a non-selective and irreversible monoamine oxidase inhibitor (MAOI) used primarily in the treatment of major depressive disorder. It is indicated for patients who do not respond to other antidepressants and is currently approved for use in several countries, though its usage has declined due to dietary restrictions and safer alternatives.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers, both sexes, after a single oral dose.</p><h4>References</h4><ol><li><p>Weber-Grandke, H, et al., &amp; Spahn-Langguth, H (1993). The pharmacokinetics of tranylcypromine enantiomers in healthy subjects after oral administration of racemic drug and the single enantiomers. <i>British journal of clinical pharmacology</i> 36(4) 363–365. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.1993.tb00377.x&quot;>10.1111/j.1365-2125.1993.tb00377.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12959316/&quot;>https://pubmed.ncbi.nlm.nih.gov/12959316</a></p></li><li><p>Mallinger, AG, et al., &amp; Ehler, J (1986). Pharmacokinetics of tranylcypromine in patients who are depressed: relationship to cardiovascular effects. <i>Clinical pharmacology and therapeutics</i> 40(4) 444–450. DOI:<a href=&quot;https://doi.org/10.1038/clpt.1986.205&quot;>10.1038/clpt.1986.205</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3757407/&quot;>https://pubmed.ncbi.nlm.nih.gov/3757407</a></p></li><li><p>Patkar, AA, et al., &amp; Masand, PS (2006). Transdermal selegiline: the new generation of monoamine oxidase inhibitors. <i>CNS spectrums</i> 11(5) 363–375. DOI:<a href=&quot;https://doi.org/10.1017/s1092852900014498&quot;>10.1017/s1092852900014498</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16641841/&quot;>https://pubmed.ncbi.nlm.nih.gov/16641841</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06AF04;
